Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

NCT00666224 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

481

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Glatiramer Acetate (DB)
DRUG: Placebo
DRUG: Glatiramer Acetate (OL)

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.